Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment

作者：Amanda Wei Yin Lim, Lon S. Schneider, Clement T. Loy · 发表于：Cochrane Database of Systematic Reviews · 年份：2024 · DOI：10.1002/14651858.cd001747.pub4 · 被引用次数：22 · 研究领域：Dementia and Cognitive Impairment Research、Alkaloids: synthesis and pharmacology、Nicotinic Acetylcholine Receptors Study

BACKGROUND: Dementia leads to progressive cognitive decline, and represents a significant health and societal burden. Its prevalence is growing, with Alzheimer's disease as the leading cause. There is no cure for Alzheimer's disease, but there are regulatory-approved pharmacological interventions, such as galantamine, for symptomatic relief. This review updates the 2006 version. OBJECTIVES: To assess the clinical effects, including adverse effects, of galantamine in people with probable or possible Alzheimer's disease or mild cognitive impairment, and to investigate potential moderators of effect. SEARCH METHODS: We systematically searched the Cochrane Dementia and Cognitive Improvement Group's Specialised Register on 14 December 2022 using the term 'galantamine'. The Register contains records of clinical trials identified from major electronic databases (including CENTRAL, MEDLINE, and Embase), trial registries, grey literature sources, and conference proceedings. We manually searched reference lists and collected information from US Food and Drug Administration documents and unpublished trial reports. We imposed no language restrictions. SELECTION CRITERIA: We included double-blind, parallel-group, randomised controlled trials comparing oral galantamine with placebo for a treatment duration exceeding four weeks in people with dementia due to Alzheimer's disease or with mild cognitive impairment. DATA COLLECTION AND ANALYSIS: Working independently, two review authors selecte...